Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells Investors
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals Q1 Earnings Call Highlights
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
Eton Pharmaceuticals Inc (ETON) Shares Fall 9.4% -- What GF Score of 73 Tells Investors
Eton Pharmaceuticals Announces CFO Succession Plan
Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?
Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why
Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?
Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
US FDA approves Eton Pharma's hormonal disorder drug
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
Eton Pharmaceuticals: An Undervalued Small Cap With High Growth
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
Acadian Asset Management LLC Sells 9,713 Shares of Eton Pharmaceuticals, Inc. $ETON
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference
Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript
Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates
Eton (ETON) Q2 Revenue Jumps 108%
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Eton Pharma Near Term Catalysts Vanish
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche